The company is putting a stop to a trial investigating what it calls the Opdualag combination, a pairing of Opdivo (nivolumab) and relatlimab, in patients with microsatellite stable metastatic colorectal cancer.
Tag Archive for: nivolumab
Although BMS did not provide specific data in yesterday’s announcement, the company said the combination regimen induced a “statistically significant and clinically meaningful improvement” in progression-free survival (PFS), compared with the investigator’s choice of chemotherapy.
The series of direct-to-consumer oncology advertisements targeting patients with advanced kidney cancer (renal cell carcinoma) and their caregivers.
Bristol Myers Squibb announced Thursday that its blockbuster checkpoint inhibitor Opdivo hit the primary endpoint in the Phase III CheckMate-76K trial for a particularly intractable form of melanoma.
